当前位置：
X-MOL 学术
›
J. Gynecol. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial.
Journal of Gynecologic Oncology ( IF 3.4 ) Pub Date : 2021-8-12 , DOI: 10.3802/jgo.2021.32.e82 Keiichi Fujiwara 1 , Hiroyuki Fujiwara 2 , Hiroyuki Yoshida 1 , Toyomi Satoh 3 , Kan Yonemori 4 , Shoji Nagao 5 , Takashi Matsumoto 6 , Hiroaki Kobayashi 7 , Hughes Bourgeois 8 , Philipp Harter 9 , Anna Maria Mosconi 10 , Isabel Palacio Vazquez 11 , Alexander Reinthaller 12 , Tomoko Fujita 13 , Philip Rowe 14 , Eric Pujade-Lauraine 15 , Isabelle Ray-Coquard 16
Journal of Gynecologic Oncology ( IF 3.4 ) Pub Date : 2021-8-12 , DOI: 10.3802/jgo.2021.32.e82 Keiichi Fujiwara 1 , Hiroyuki Fujiwara 2 , Hiroyuki Yoshida 1 , Toyomi Satoh 3 , Kan Yonemori 4 , Shoji Nagao 5 , Takashi Matsumoto 6 , Hiroaki Kobayashi 7 , Hughes Bourgeois 8 , Philipp Harter 9 , Anna Maria Mosconi 10 , Isabel Palacio Vazquez 11 , Alexander Reinthaller 12 , Tomoko Fujita 13 , Philip Rowe 14 , Eric Pujade-Lauraine 15 , Isabelle Ray-Coquard 16
Affiliation
The addition of maintenance olaparib to bevacizumab demonstrated a significant progression-free survival (PFS) benefit in patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1/ENGOT-ov25 trial (NCT02477644). We evaluated maintenance olaparib plus bevacizumab in the Japan subset of PAOLA-1.
中文翻译：
奥拉帕尼加贝伐单抗作为新诊断晚期卵巢癌患者的维持治疗：来自 PAOLA-1/ENGOT-ov25 试验的日本子集。
在 PAOLA-1/ENGOT-ov25 试验 (NCT02477644) 中，向贝伐单抗添加维持性奥拉帕尼对新诊断的晚期卵巢癌患者具有显着的无进展生存期 (PFS) 益处。我们在 PAOLA-1 的日本子集中评估了维持性奥拉帕尼加贝伐单抗。
更新日期：2021-08-12
中文翻译：
奥拉帕尼加贝伐单抗作为新诊断晚期卵巢癌患者的维持治疗：来自 PAOLA-1/ENGOT-ov25 试验的日本子集。
在 PAOLA-1/ENGOT-ov25 试验 (NCT02477644) 中，向贝伐单抗添加维持性奥拉帕尼对新诊断的晚期卵巢癌患者具有显着的无进展生存期 (PFS) 益处。我们在 PAOLA-1 的日本子集中评估了维持性奥拉帕尼加贝伐单抗。
京公网安备 11010802027423号